Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Debt Ratio (2018 - 2024)

Neurocrine Biosciences' Debt Ratio history spans 6 years, with the latest figure at 0.04 for Q1 2024.

  • For Q1 2024, Debt Ratio changed N/A year-over-year to 0.04; the TTM value through Mar 2024 reached 0.04, changed N/A, while the annual FY2023 figure was 0.05, 26.85% down from the prior year.
  • Debt Ratio reached 0.04 in Q1 2024 per NBIX's latest filing, down from 0.05 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.28 in Q3 2020 to a low of 0.04 in Q1 2024.
  • Average Debt Ratio over 4 years is 0.12, with a median of 0.07 recorded in 2022.
  • The largest YoY upside for Debt Ratio was 24.43% in 2023 against a maximum downside of 26.85% in 2023.
  • A 4-year view of Debt Ratio shows it stood at 0.28 in 2020, then tumbled by 74.72% to 0.07 in 2022, then dropped by 26.85% to 0.05 in 2023, then crashed by 32.4% to 0.04 in 2024.
  • Per Business Quant, the three most recent readings for NBIX's Debt Ratio are 0.04 (Q1 2024), 0.05 (Q4 2023), and 0.06 (Q3 2023).